Carvedilol protects the peritubular capillaries and kidney structure in spontaneously hypertensive rats.

Int J Cardiol

Instituto de Investigaciones Cardiológicas "Prof. Dr. Alberto C. Taquini" (ININCA), University of Buenos Aires - CONICET, Buenos Aires, Argentina.

Published: February 2015

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2014.12.049DOI Listing

Publication Analysis

Top Keywords

carvedilol protects
4
protects peritubular
4
peritubular capillaries
4
capillaries kidney
4
kidney structure
4
structure spontaneously
4
spontaneously hypertensive
4
hypertensive rats
4
carvedilol
1
peritubular
1

Similar Publications

Hypoxia/reoxygenation (HR) often occurs under cardiac pathological conditions, and HR-induced oxidative stress usually leads to cardiomyocyte damage. Carvedilol, a non-selective β-blocker, is used clinically to treat cardiac ischemia diseases. Moreover, Carvedilol has also been reported to have an antioxidant ability by reducing lipid peroxidation.

View Article and Find Full Text PDF

Basic pharmacological evaluation of modified phenyl carbamic acid derivatives on cardiovascular functions under in vitro conditions in rats.

Gen Physiol Biophys

January 2025

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia.

The study aimed to evaluate the basic pharmacological effects of modified phenyl carbamic acid derivates with a basic part made of N-phenylpiperazine (compounds 6a, 6b, 6c, 6d) in Wistar rats. The compounds were evaluated for their ability to decrease the phenylephrine-induced contraction of the aortic strips of rats after repeated administration of the compounds and their ability to inhibit the positive chronotropic effect of isoproterenol on spontaneously beating rat atria. The ability to inhibit the vasoconstriction effect of phenylephrine was confirmed in all compounds in the range from 10.

View Article and Find Full Text PDF

Background: The use of beta-blockers in treating resistant hypertension remains poorly understood. While PATHWAY-2 showed a systolic blood pressure benefit with bisoprolol, further research is needed to evaluate other beta-blockers in terms of the effect of systolic blood pressure, assess diastolic blood pressure effects, and guide management in patients intolerant to CCBs as well.

Objectives: Our study aimed to evaluate the efficacy of Carvedilol (non-selective beta-blocker with alpha-1 blocking function) in the management of resistant hypertension, including in patients intolerant to calcium channel blockers.

View Article and Find Full Text PDF

This study investigates the impact of a high-sugar environment on H9C2 cardiomyocytes and explores the protective effects of carvedilol in the context of diabetic cardiomyopathy (Dia-CM). Transcriptomic analysis identified 21,655 differentially expressed genes associated with Dia-CM, demonstrating significant separation among samples. H9C2 cardiomyocytes were cultured in a high-sugar environment to simulate Dia-CM conditions.

View Article and Find Full Text PDF

A strain-guided trial of cardioprotection in early-stage breast cancer patients on anti-HER2 therapy (PROTECT HER2).

Cardiooncology

November 2024

Division of Cardiovascular Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, 676 N. St. Clair, Suite 600, Chicago, IL, 60611, USA.

Background: Global longitudinal strain (GLS) has been used to identify patients at risk for cancer-therapy related cardiac dysfunction (CTRCD). However, there is limited data on the effectiveness of initiating cardioprotective therapy based on a strain-guided strategy in early stage HER2+ breast cancer patients. This randomized clinical trial assessed if treatment with carvedilol based on a strain-guided strategy can prevent development of CTRCD in HER2+ breast cancer patients on non-anthracycline based regimens.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!